Tazarotene - AlmirallAlternative Names: LAS41006
Latest Information Update: 28 Jul 2015
At a glance
- Originator Almirall S.A.
- Class Antiacnes; Antipsoriatics; Keratolytics; Nicotinic-acids; Retinoids; Small molecules
- Mechanism of Action Retinoic acid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Psoriasis
Most Recent Events
- 07 May 2015 Almirall completes a phase II trial in Psoriasis in Germany (NCT02235480)